



邱俊龍 Chiu, Chun-Lung

助理教授

專長：癌症生物學、癌症標靶治療、慢性腎病
疾病動物模式、生理學、遺傳學

主要教授課程：

大學部：獸醫生理學、動物遺傳學、臨床討論

研究所：基因工程技術學、實驗動物學特論

Tel: 04-22840368 分機 21

e-mail: chuchiu@dragon.nchu.edu.tw

簡要學經歷及重要榮譽

學歷

博士：美國加州大學戴維斯分校病理生物學研究所

碩士：國立中興大學獸醫學系研究所

學士：國立中興大學獸醫學系

經歷

國立中興大學獸醫學系助理教授	2026.08-迄今
國立屏東科技大學獸醫學系助理教授	2025.08-2026.07
美國國防部國家癌症研究計畫主持人	2022.07-2025.07
美國史丹佛大學博士後研究員	2021.03-2025.07
美國加州大學戴維斯分校博士後研究員	2018.08-2021.01

榮譽

Postdoctoral and Clinical Fellowship Award, U.S. Department of Defense, 2022-2025

Outstanding Internal Medicine Professional Research Award, UC Davis, 2018

First Place Award, 11th Annual Spotlight on Junior Investigators Cancer Research Symposium, 2017

Graduate Fellowship, Integrative Pathobiology Graduate Group, UC Davis, 2015

Graduate Student Travel Award, UC Davis, 2015

Outstanding Poster Award, 6th Annual Lung Research Symposium, UC Davis, 2015

Scholarship Award, American Thoracic Society 2015 International Conference, 2015

Graduate Research Grant (Graduate Fellowship), UC Davis, School of Veterinary Medicine, 2014, 2016

Graduate Fellowship, Comparative Pathology Graduate Group, UC Davis, 2013

教育部公費留學 教育部 中華民國 2012-2015

研究興趣

我的研究聚焦於癌症生物學、癌症分子標靶治療及慢性腎臟病。透過整合分子生物學與多組學研究方法，我們探討關鍵致癌分子及訊號傳遞路徑在腫瘤生長、轉移與治療抗藥性中的角色，並致力於發掘具潛力的診斷生物標誌與治療標的。我們建立並應用多種疾病動物模式，包括病人來源異種移植模式及基因工程動物模式，用於抗癌藥物與免疫治療的臨床前評估。未來，我們將持續推動比較腫瘤學研究，發展精準診斷平台及智慧創新治療策略，並與國內外醫學、獸醫學及產業界夥伴合作。這些研究旨在加速研究成果轉譯至臨床應用、提升癌症治療成效，並促進人類與動物的健康及福祉。

近期代表著作

1. **Chiu CL***, Zhang D*, Zhao H, Wei Y, Polasko AL, Thomsen MT, Yang V, Yang KK, Hauck S, Peterson EE, Wen RM, Qiu Z, Corey E, Miao YR, Rankin EB, Peehl DM, Huang J, Giaccia AJ, Brooks JD.

- Targeting AXL inhibits the growth and metastasis of prostate cancer in bone. *Clin Cancer Res*. 2025 Apr 1;31(7):1346-1358. (SCI Impact factor: 10.9, 2025; Oncology 33/333, 9.91%).
2. Zhang D*, Chiu CL*, Garcia Marques FJ, Bermudez A, Hoerner CR, Hadi N, Wang E, Metzner TJ, Trabanino L, Leppert JT, Zhao H, Tibshirani R, Fan AC, Pitteri SJ, Brooks JD. Identification of serum protein biomarkers for clear cell renal cell carcinoma using patient-derived xenografts. *J Clin Invest*. 2025 Nov 4;136(1):e193567. (SCI Impact factor: 14.3, 2025; Medicine, Research & Experimental 10/191, 5.24%).
 3. Zhang D*, Chiu CL*, Wen RM, Qiu Z, Garcia-Marques FJ, Bermudez A, Zhao M, Zhao H, Dixon SJ, Peehl Dm, Rankin EB, Pitteri SJ, Brooks JD. FTO inhibition attenuates renal fibrosis by downregulating ferroptosis activator ACSL4 and profibrotic factor TGFBI. *iScience*. 2025 Sep 7;28(10):113515. (SCI Impact factor: 4.5, 2025; Multidisciplinary Sciences 24/140, 17.14%).
 4. Chiu CL*, Li CG*, Verschueren E, Wen RM, Zhang D, Gordon CA, Zhao H, Giaccia AJ, Brooks JD. NUSAP1 binds ILF2 to modulate R-loop-dependent DNA damage in prostate cancer. *Int J Mol Sci*. 2023 Mar 26;24(7):6258. (SCI Impact factor: 5.6, 2025; Biochemistry & Molecular Biology 72/328, 21.95%).
 5. Chiu CL, Zhao H, Chen CH, Wu R, Brooks JD. The role of MARCKS in metastasis and treatment resistance of solid tumors. *Cancers (Basel)*. 2022 Oct 8;14(19):4925. (SCI Impact factor: 4.8, 2025; Oncology 92/333, 27.63%).
 6. Chiu CL*, Hong SY*, Tan Y, Lee YJ, Shih YP, Tepper CG, Lo SH. C-terminal tensin-like (CTEN) knockin alleviates cystic kidney defects in Tensin-1 knockout mice. *Genes Dis*. 2022 Jun 17;10(3):643-646. (SCI Impact factor: 14.6, 2025; Genetics & Heredity 4/192, 2.08%).
 7. Wu ZY*, Chiu CL*, Lo Ethan, Lee Julie YR, Yamada Soichiro, and Lo SH. Hyperactivity of Mek in TNS1 knockouts leads to potential treatments for cystic kidney diseases. *Cell Death Dis*. 2019 Nov 18;10(12):871. (SCI Impact factor: 12.2, 2025; Cell Biology 27/207, 13.04%).
 8. Thomsen MT, Busk M, Zhang D, Chiu CL, Zhao H, Garcia-Marques FJ, Bermudez A, Pitteri SJ, Borre M, Brooks JD, Nyengaard JR. The olfactory receptor OR51E2 regulates prostate cancer aggressiveness through STAT3 modulation in a prostate cancer cell line and in xenograft tumors. *BMC Cancer*. 2025 Mar 24;25(1):535. (SCI Impact factor: 4.1, 2025; Oncology 111/333, 33.33%).
 9. Polasko AL, Zhang D, Ramraj A, Chiu CL, Garcia-Marques FJ, Bermudez A, Kapp K, Peterson E, Qiu Z, Pollack AS, Zhao H, Pollack JR, Pitteri SJ, Brooks JD. Establishing and Characterizing the Molecular Profiles, Cellular Features, and Clinical Utility of a Patient-Derived Xenograft Model Using Benign Prostatic Tissues. *Lab Invest*. 2024 Oct;104(10):102129. (SCI Impact factor: 4.1, 2025; Pathology 13/89, 14.61%).
 10. Lee CC, Chen CH, Kenyon NJ, Wang CN, Tsai HC, Chiu CL, Chen Y, Forteza RM, Wu R. Inhibition of MARCKS phosphorylation attenuates of dendritic cell migration in a murine model of acute asthma. *Eur J Pharmacol*. 2024 Oct 5;980:176867. (SCI Impact factor: 5.7, 2025; Pharmacology & Pharmacy 52/356, 14.61%).
 11. Wen RM, Qiu Z, Marti GEW, Peterson EE, Marques FJG, Bermudez A, Wei Y, Nolley R, Lam N, Polasko AL, Chiu CL, Zhang D, Cho S, Karageorgos GM, McDonough E, Chadwick C, Ginty F, Jung KJ, Machiraju R, Mallick P, Crowley L, Pollack JR, Zhao H, Pitteri SJ, Brooks JD. AZGP1 deficiency promotes angiogenesis in prostate cancer. *J Transl Med*. 2024 Apr 24;22(1):383. (SCI Impact factor: 9.7, 2025; Medicine, Research & Experimental 20/191, 10.47%).
 12. Wen R, Zhao H, Zhang D, Chiu CL, Brooks JD. Sialylated glycoproteins as biomarkers and drivers of

- progression in prostate cancer. *Carbohydr Res.* 2022 Sep;519:108598. (SCI Impact factor: 3.4, 2025; Chemistry, Applied 31/77, 40.26%).
13. Lee CC, Lee YL, Wang CN, Tsai HC, **Chiu CL**, Liu LF, Lin HY, Wu R. Polygonum multiflorum decreases airway allergic symptoms in a murine model of asthma. *Am J Chin Med.* 2016;44(1):133- 47. (SCI Impact factor: 7.8, 2025; Integrative & Complementary Medicine 2/48, 4.17%).
 14. Chen CH, Statt S, **Chiu CL**, Thai P, Arif M, Adler KB, and Wu R. Targeting myristoylated alanine- rich C kinase substrate phosphorylation site domain in lung cancer: Mechanisms and therapeutic implications. *Am J Respir Crit Care Med.* 2014 Nov 15;190(10):1127-38. (SCI Impact factor: 21.7, 2025; Respiratory System 4/107, 3.74%).
 15. Chen CH, **Chiu CL**, Alder KB, and Wu R. A novel predictor of cancer malignancy and potential therapeutic target: Up-regulation of MARCKS phosphorylation in lung cancer. *Am J Respir Crit Care Med.* 2014 Apr 15;189(8):1002-4. (SCI Impact factor: 21.7, 2025; Respiratory System 4/107, 3.74%).
 16. Chang GR, Yang CC, Hsu SH, Lin C, **Chiu CL**, Chan FT and Mao FC. Fecal reproductive steroid profiles for monitoring reproductive patterns in female Formosan black bears (*Ursus thibetanus formosanus*). *Ann. Zool. Fennici* 2011; 48: 275-286. (SCI Impact factor: 0.4, 2025; Ecology 196/205, 95.61%).
- (* equal contribution)

更新日期：2026 年 8 月 1 日